دورية أكاديمية
Clinical Performance of Technetium-99m-Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice.
العنوان: | Clinical Performance of Technetium-99m-Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice. |
---|---|
المؤلفون: | Schober JP; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Braun A; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Ginsburg KB; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Bell S; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Castro Bigalli AA; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Chen M; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Wang R; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Magee D; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Bukavina L; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Handorf E; Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Yu JQ; Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Chen DYT; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Greenberg RE; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Smaldone MC; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Viterbo R; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Correa AF; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Uzzo RG; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Kutikov A; Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. |
المصدر: | The Journal of urology [J Urol] 2023 Sep; Vol. 210 (3), pp. 438-445. Date of Electronic Publication: 2023 Jun 28. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 0376374 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-3792 (Electronic) Linking ISSN: 00225347 NLM ISO Abbreviation: J Urol Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2019- : [Philadelphia, PA] : Wolters Kluwer Original Publication: Baltimore : Lippincott Williams & Wilkins |
مواضيع طبية MeSH: | Carcinoma, Renal Cell*/diagnostic imaging , Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/diagnostic imaging , Kidney Neoplasms*/pathology , Adenoma, Oxyphilic*/diagnostic imaging, Humans ; Technetium Tc 99m Sestamibi ; Single Photon Emission Computed Tomography Computed Tomography ; Tomography, X-Ray Computed/methods ; Tomography, Emission-Computed, Single-Photon/methods ; Radiopharmaceuticals |
مستخلص: | Purpose: Technetium-99m-sestamibi single-photon emission CT/x-ray CT is an emerging clinical tool to differentiate oncocytic tumors from renal cell carcinomas. We report data from a large institutional cohort of patients who underwent technetium-99m-sestamibi scans during evaluation of renal masses. Materials and Methods: Patients who underwent technetium-99m-sestamibi single-photon emission CT/x-ray CT between February 2020 and December 2021 were included in the analysis. Scans were defined as "hot" for oncocytic tumor when technetium-99m-sestamibi uptake was qualitatively equivalent or higher between the mass of interest and normal renal parenchyma, suggesting oncocytoma, hybrid oncocytic/chromophobe tumor, or chromophobe renal cell carcinoma. Demographic, pathological, and management strategy data were compared between "hot" and "cold" scans. For individuals who underwent diagnostic biopsy or extirpative procedures, the concordance between radiological findings and pathology was indexed. Results: A total of 71 patients (with 88 masses) underwent technetium-99m-sestamibi imaging with 60 (84.5%) patients having at least 1 "cold" mass on imaging and 11 (15.5%) patients exhibiting only "hot" masses. Pathology was available for 7 "hot" masses, with 1 biopsy specimen (14.3%) being discordant (clear cell renal cell carcinoma). Five patients with "cold" masses underwent biopsy. Out of 5 biopsied masses, 4 (80%) were discordant oncocytomas. Of the extirpated specimens, 35/40 (87.5%) harbored renal cell carcinoma and 5/40 (12.5%) yielded discordant oncocytomas. In sum, 20% of pathologically sampled masses that were "cold" on technetium-99m-sestamibi imaging still harbored oncocytoma/hybrid oncocytic/chromophobe tumor/chromophobe renal cell carcinoma. Conclusions: Further work is needed to define utility of technetium-99m-sestamibi in real-world clinical practice. Our data suggest this imaging strategy is not yet ready to replace biopsy. |
التعليقات: | Comment in: J Urol. 2023 Sep;210(3):444-445. doi: 10.1097/JU.0000000000003557.01. (PMID: 37378577) Comment in: Transl Androl Urol. 2024 Jun 30;13(6):1053-1055. doi: 10.21037/tau-23-623. (PMID: 38983466) |
فهرسة مساهمة: | Keywords: biopsy; kidney neoplasms; oncocytoma; radionuclide imaging; renal; watchful waiting |
المشرفين على المادة: | 971Z4W1S09 (Technetium Tc 99m Sestamibi) 0 (Radiopharmaceuticals) |
تواريخ الأحداث: | Date Created: 20230628 Date Completed: 20230810 Latest Revision: 20240710 |
رمز التحديث: | 20240710 |
DOI: | 10.1097/JU.0000000000003557 |
PMID: | 37378576 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!